Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does combining docetaxel with cisplatin and fluorouracil improve clinical benefit in advanced gastroesophageal cancer?

Nature Clinical Practice Oncology volume 5, pages 132–133 (2008)Cite this article

boxed-textAjani JA et al. (2007) Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma : The V-325 Study Group. J Clin Oncol 22: 3205–3209

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Van Cutsem E et al. (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24: 4991–4997

    Article  CAS  Google Scholar 

  2. Vanhoefer U et al. (2000) Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18: 2648–2657

    Article  CAS  Google Scholar 

  3. Wagner A et al. (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24: 2903–2909

    Article  CAS  Google Scholar 

  4. Cunningham D et al. (2006) Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL-2 trial—2006 ASCO Annual Meeting Proceedings [abstract #LBA4017]. J Clin Oncol 24: 1825

    Google Scholar 

  5. Tebbutt N et al. (2007) ATTAX: Randomised phase II study evaluating weekly docetaxel-based chemotherapy combination in advanced esophago–gastric cancer, final results of an AGITG trial. 2007 ASCO Annual Meeting Proceedings [abstract #4528] J Clin Oncol 25 (Suppl): 2045

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Mandy Aujla, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. G Ratnayake is a Clinical Research Fellow, and D Cunningham is Head of the Lymphoma and Gastrointestinal Unit, at the Royal Marsden Hospital, Sutton, UK.,

    Gihan Ratnayake & David Cunningham

Authors
  1. Gihan Ratnayake
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Cunningham
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Cunningham.

Ethics declarations

Competing interests

D Cunningham is a Consultant, and is on the speaker's bureau and receives grant/research support from the following companies: Pfizer Roche, and Sanofi-Aventis.

G Ratnayake declared no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ratnayake, G., Cunningham, D. Does combining docetaxel with cisplatin and fluorouracil improve clinical benefit in advanced gastroesophageal cancer?. Nat Rev Clin Oncol 5, 132–133 (2008). https://doi.org/10.1038/ncponc1044

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc1044

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing